Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-992 pembrolizumab plus chemoradiotherapy in muscle-invasive bladder cancer
2019-004023-20Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab in muscle-invasive bladder cancer (MIBC) and bladder cancer (2 arms), sponsored by Merck & Co. Primary endpoint: Bladder Intact Event-Free Survival. Started Dec 2019; status: active.
02
Drugs
03
Conditions
muscle-invasive bladder cancer (MIBC)bladder cancer
Beyond the preview
Go deeper on 2019-004023-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004023-20.